BioRestorative Therapies (NASDAQ:BRTX) Releases Quarterly Earnings Results

BioRestorative Therapies (NASDAQ:BRTX) issued its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.22, Zacks reports. The company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.30 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 93.89%.

BioRestorative Therapies Stock Performance

NASDAQ:BRTX traded down $0.06 during mid-day trading on Thursday, hitting $1.48. 33,333 shares of the stock were exchanged, compared to its average volume of 768,575. The firm’s 50-day simple moving average is $1.63 and its 200 day simple moving average is $1.60. BioRestorative Therapies has a fifty-two week low of $1.03 and a fifty-two week high of $3.67. The stock has a market capitalization of $10.24 million, a price-to-earnings ratio of -1.00 and a beta of 63.40.

Analyst Upgrades and Downgrades

Separately, Roth Mkm increased their price target on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, August 14th.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.